Case series demonstrates feasibility and safety of switching to continuous subcutaneous foslevodopa infusion, implying possible symptomatic benefits in advanced Parkinson's disease.
Background Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non‐surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real‐world switch data remain limited. Objectives To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI. Methods We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non‐motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6). Results Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ‐8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions. Conclusion Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.
No takes yet. Share an insight, caveat, or question.
Baille et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: